Shares of Nektar Therapeutics (NASDAQ:NKTR) gapped down before the market opened on Friday . The stock had previously closed at $93.74, but opened at $93.87. Nektar Therapeutics shares last traded at $93.87, with a volume of 4924815 shares.
Several analysts have recently weighed in on NKTR shares. Canaccord Genuity restated a “buy” rating and set a $80.00 price objective (up previously from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Mizuho set a $89.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 29th. Jefferies Group boosted their price objective on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Cowen restated a “buy” rating and set a $101.00 price objective on shares of Nektar Therapeutics in a research report on Friday, March 2nd. Finally, Zacks Investment Research downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Nektar Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $63.75.
The company has a debt-to-equity ratio of 2.79, a current ratio of 5.82 and a quick ratio of 5.63.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.14. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The firm had revenue of $95.47 million during the quarter, compared to the consensus estimate of $36.96 million. During the same quarter in the prior year, the firm earned ($0.28) EPS. Nektar Therapeutics’s revenue for the quarter was up 154.9% on a year-over-year basis. research analysts forecast that Nektar Therapeutics will post -1.33 earnings per share for the current fiscal year.
In related news, CEO Howard W. Robin sold 83,333 shares of the company’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $75.82, for a total value of $6,318,308.06. Following the completion of the sale, the chief executive officer now owns 333,268 shares in the company, valued at approximately $25,268,379.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Stephen K. Doberstein sold 2,426 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $82.94, for a total transaction of $201,212.44. Following the completion of the sale, the senior vice president now owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 369,592 shares of company stock valued at $34,241,981. 6.10% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in NKTR. California Public Employees Retirement System increased its stake in Nektar Therapeutics by 2.3% in the 3rd quarter. California Public Employees Retirement System now owns 195,200 shares of the biopharmaceutical company’s stock valued at $4,685,000 after buying an additional 4,300 shares during the period. Advisor Partners LLC acquired a new position in Nektar Therapeutics in the 4th quarter valued at $393,000. Carillon Tower Advisers Inc. acquired a new position in Nektar Therapeutics in the 4th quarter valued at $43,024,000. Aperio Group LLC increased its stake in Nektar Therapeutics by 14.6% in the 4th quarter. Aperio Group LLC now owns 49,830 shares of the biopharmaceutical company’s stock valued at $2,976,000 after buying an additional 6,345 shares during the period. Finally, Teachers Advisors LLC increased its stake in Nektar Therapeutics by 38.0% in the 4th quarter. Teachers Advisors LLC now owns 930,424 shares of the biopharmaceutical company’s stock valued at $55,565,000 after buying an additional 256,078 shares during the period. Hedge funds and other institutional investors own 96.22% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/nektar-therapeutics-nktr-shares-gap-down-to-93-87.html.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.